Value of inflammatory biomarkers in predicting the outcome of patients with muscle-invasive bladder cancer receiving different neoadjuvant treatment regimens

Abstract:

Objective To investigate the value of inflammatory biomarkers in predicting the efficacy of neoadjuvant therapy in patients with muscle-invasive bladder cancer.Methods A retrospective analysis was performed for the clinical data of patients with muscle-invasive bladder cancer who attended Department of Urology，The First Affiliated Hospital of Chongqing Medical University，from January 2020 to February 2023 and received neoadjuvant therapy. The influence of related inflammatory biomarkers on the efficacy of neoadjuvant therapy was analyzed，including neutrophil-to-lymphocyte ratio（NLR），derived neutrophil-to-lymphocyte ratio（dNLR），and systemic immune-inflammation index（SII），and the receiver operating characteristic（ROC） curve was used to determine the optimal cut-off values. Then the patients were divided into high and low inflammatory biomarker subgroups to investigate the differences in clinicopathological parameters and the efficacy of neoadjuvant therapy. Finally，a comparative analysis was performed to investigate the influence of inflammatory biomarkers on the outcome of patients receiving neoadjuvant therapy.Results There were no significant differences in clinicopathological parameters between the high and low inflammatory biomarker subgroups（P>0.05）. There were significant differences in objective response rate（ORR） and disease control rate（DCR） after neoadjuvant therapy between the high and low inflammatory biomarker subgroups（P<0.05），and higher levels of inflammatory biomarker were associated with a less favorable therapeutic outcome. In addition，there were no significant differences in ORR and DCR between the four neoadjuvant treatment regimens（P>0.05）.Conclusion The peripheral blood inflammatory biomarkers NLR，dNLR，and SII before neoadjuvant therapy can be used as potential indicators to judge the efficacy of neoadjuvant therapy.